Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020097209 - TREATING PROSTATE CANCER USING A COMBINATION OF A DNA VACCINE, PD-1 INHIBITOR AND AN IDO INHIBITOR

Publication Number WO/2020/097209
Publication Date 14.05.2020
International Application No. PCT/US2019/060077
International Filing Date 06.11.2019
IPC
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61K 31/167 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
167having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/4152 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4151,2-Diazoles
4152having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 31/64 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61P 35/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
CPC
A61K 2039/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
A61K 2039/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
53DNA (RNA) vaccination
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
A61K 31/167
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
167having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/4152
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
4151,2-Diazoles
4152having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 31/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
Applicants
  • WISCONSIN ALUMNI RESEARCH FOUNDATION [US]/[US]
Inventors
  • MCNEEL, Douglas, G.
  • ZAHM, Christopher, D.
  • JOHNSON, Laura
Agents
  • BABEL, Angeline, R.
Priority Data
62/756,15706.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TREATING PROSTATE CANCER USING A COMBINATION OF A DNA VACCINE, PD-1 INHIBITOR AND AN IDO INHIBITOR
(FR) TRAITEMENT DU CANCER DE LA PROSTATE FAISANT APPEL À UNE ASSOCIATION D'UN VACCIN À ADN, D'UN INHIBITEUR DE PD-1 ET D'UN INHIBITEUR DE L'IDO
Abstract
(EN)
The present invention provides compositions and methods of treating prostate cancer using a combination of a DNA vaccine, PD-l inhibitor and an IDO inhibitor. Further, methods of measuring IDO activity as a way to identify a subpopulation of subjects with prostate cancer that may benefits from the treatment methods described herein are provided.
(FR)
La présente invention concerne des compositions et des procédés de traitement du cancer de la prostate faisant appel à une association d'un vaccin à ADN, d'un inhibiteur de PD-1 et d'un inhibiteur de l'IDO. L'invention concerne en outre des procédés de mesure de l'activité de l'IDO en tant que moyen pour identifier une sous-population de sujets atteints d'un cancer de la prostate qui peuvent bénéficier des procédés de traitement selon l'invention.
Latest bibliographic data on file with the International Bureau